Wall Street Zen Slaps Sell Ratings on CME, Novavax, and SNDL – 3 Stocks to Watch
In a single day, Wall Street Zen downgraded CME Group to strong sell, and Novavax and SNDL to sell, sending bearish signals across exchanges, biotech, and cannabis. Markets digest the calls amid wide analyst disagreement.
Key Takeaways
- In a single day, Wall Street Zen downgraded CME Group to strong sell, and Novavax and SNDL to sell, sending bearish signals across exchanges, biotech, and cannabis.
- Markets digest the calls amid wide analyst disagreement.
Mentioned
Key Intelligence
Key Facts
- 1Wall Street Zen downgraded CME Group to Strong Sell from Sell; Novavax and SNDL both cut to Sell from Hold on August 1, 2026.
- 2CME Group traded at $266.17 on July 31 with a market cap of $95.71 billion, P/E of 22.58, and a consensus Hold rating and $291.81 price target.
- 3Novavax (NVAX) stock opened at $7.41, market cap $1.22 billion, negative P/E of -12.78, and an average Hold rating with a $13.00 target — a 75% upside to target.
- 4SNDL opened at $1.23, market cap $315.31 million, P/E -20.42, with a consensus Hold rating and a $5.00 target price, but only three analysts cover it.
- 5Both CME and Novavax trade below their 50-day and 200-day moving averages; SNDL’s 50-day MA is $1.36 and 200-day MA is $1.44 versus its $1.23 open.
- 6Novavax beat Q1 2026 EPS estimates by $0.19 (actual -$0.06 vs. -$0.25 est.) on revenue of $118.9 million vs. $79.81 million expected.
| Metric | |||
|---|---|---|---|
| Price (Jul 31) | $266.17 | $7.41 | $1.23 |
| Market Cap | $95.71B | $1.22B | $315.31M |
| P/E Ratio | 22.58 | -12.78 | -20.42 |
| Consensus Rating | Hold | Hold | Hold |
| Consensus Target | $291.81 | $13.00 | $5.00 |
Analysis
When a small research shop like Wall Street Zen issues three simultaneous sell ratings, finance pros take note—not for the ratings themselves, but for the patterns they expose. CME’s strong sell cut flies in the face of 11 buy ratings; SNDL’s sell lands just above its 52-week low; and Novavax’s sell underscores the biotech funding winter. For traders, these calls spotlight stocks where consensus may be too optimistic, and where negative momentum could accelerate.
Wall Street Zen, a research firm known for its aggressive calls, unleashed a wave of bearish downgrades across disparate sectors on August 1, 2026, slapping sell ratings on three distinct companies: financial exchange giant CME Group (CME), vaccine developer Novavax (NVAX), and Canadian cannabis operator SNDL (SNDL). The actions sent ripples through markets already grappling with mixed analyst sentiment, highlighting vulnerabilities in each name despite vastly different fundamentals and industry backdrops. CME Group, with its $95.7 billion market cap and fortress balance sheet, was cut to strong sell from sell, a striking vote of no confidence on a company that thrives on volatility and trading volumes. Novavax, a $1.22 billion biotech still navigating a post-pandemic revenue cliff, was moved from hold to sell, deepening concerns about its ability to sustain momentum beyond its COVID-19 franchise. SNDL, a $315 million cannabis player struggling with profitability, slipped from hold to sell as renewed regulatory uncertainty and competitive pressures cloud its outlook.
For CME, the downgrade stands in stark contrast to eleven buy ratings, four holds, and a consensus price target of $291.81—about 10% above its July 31, 2026 close of $266.17.
What to Watch
The downgrades come amid a mixed mosaic of analyst ratings for all three. For CME, the downgrade stands in stark contrast to eleven buy ratings, four holds, and a consensus price target of $291.81—about 10% above its July 31, 2026 close of $266.17. The stock’s low beta of 0.23 and healthy 1.02 current ratio suggest limited financial risk, but Wall Street Zen’s extreme bearishness may reflect anticipated erosion in trading volumes or competitive threats from decentralized finance platforms. Novavax, meanwhile, garners a more divided view: one strong buy, five buys, one hold, and three sells. The consensus target of $13.00 implies a 75% upside from its $7.41 last close, yet Wall Street Zen’s sell rating underscores deep skepticism about the company’s pipeline beyond its COVID-19 vaccine, which only delivered $118.9 million in Q1 2026—beating estimates but down dramatically from prior years. SNDL, trading near its 52-week low of $1.17 and just above the $1.23 Friday open, has a sparse analyst following with one buy, one hold, one sell, and a consensus $5.00 target that appears aspirational given a negative P/E of -20.42 and a history of dilution.
Market impact: CME’s downgrade, despite its size, is unlikely to shake the stock significantly given the dominant buy consensus, but the strong sell label could spook momentum traders. For Novavax, the sell rating adds to the narrative of biotech investors fleeing small-cap names without near-term catalysts, especially as interest rate uncertainty persists into 2026. SNDL’s downgrade further dampens sentiment in the cannabis sector, which remains starved for federal U.S. reform and plagued by oversupply in Canada. All three stocks are trading below their 50- and 200-day moving averages, signaling bearish technical setups. The simultaneous downgrades by a single research house may also invite scrutiny of Wall Street Zen’s methodology and track record, particularly given the wide disparity with consensus for CME. Forward-looking, investors should watch for activist responses, insider transactions, and any subsequent rating changes from larger houses that could solidify the bearish thesis or trigger contrarian buying.
Cite This Page
"Wall Street Zen Slaps Sell Ratings on CME, Novavax, and SNDL – 3 Stocks to Watch." Finance Intelligence Brief, August 4, 2026. https://getfinancebrief.com/story/wall-street-zen-downgrades-cme-nvax-sndl-finance
From the Network
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |